COVID-19 vaccine potency and breadth improved by nanoparticle-conjugated adjuvants

Science Instruments in laboratory room. Science Research Concept.

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

New model for detecting and estimating pathogen variant dynamics and risk

Previous article

Does the duration between SARS-CoV-2 infection and vaccination affect immunity?

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News